AgomAb Therapeutics NV (NASDAQ:AGMB) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David R. Epstein Other companies: Tempus AI, Inc. (Director · Since at least Jun 13, 2024); Seagen Inc (CEO, Director · Nov 10, 2023 – Dec 14, 2023 · Past) | Director · Since at least Mar 18, 2026 |
| Marino Garcia Other companies: Dianthus Therapeutics, Inc. (President & Chief Executive Officer, Board Member · Since at least Sep 11, 2023); Synergy Pharmaceuticals Inc (EVP and Chief Strategy Officer · Jan 5, 2018 – Jan 5, 2018 · Past) | Director · Since at least Sep 11, 2026 |
| Naimish Patel Other companies: CRISPR Therapeutics AG (Chief Medical Officer · Since at least Jun 1, 2026) | Non-Executive Director · Since at least Sep 11, 2026 |
| Weegen Felice Isabel Verduyn-van Other companies: Evommune, Inc. (Director · Since at least Nov 5, 2025) | Director · Since at least Mar 18, 2026 |
| Andrea Sáez | Chief Development Officer · Since at least Nov 4, 2026 |
| Andrea Saez Borderias | Chief Development Officer · Since at least Mar 18, 2026 |
| Angelika Jahreis | Non-Executive Director · Since at least Nov 5, 2026 |
| Colin Bond | Director · Since at least Mar 18, 2026 |
| ContactsInvestors Sofie Van Gijsel | VP of Investor RelationsE-mail · May 27, 2026 – Nov 5, 2026 · Past |
| Ellen Lefever | General Counsel · Since at least Mar 18, 2026 |
| Felice Verduyn | Representing EQT Life Sciences · Since at least Nov 5, 2026 |
| Ohad Hammer | Representing Pontifax · Since at least May 27, 2026 |
| Paul van der Horst | Chief Business Officer · Since at least Mar 18, 2026 |
| Philippe Wiesel | Chief Medical Officer · Since at least Mar 18, 2026 |
| Pierre Kemula | Chief Financial Officer · Since at least Mar 18, 2026 |
| Sofie Van Gijsel | VP of Investor Relations · Since at least Nov 4, 2026 |
| Tim Knotnerus | Chief Executive Officer · Since at least Sep 11, 2026 |